Investigating the molecular drivers of high-level clinical responses to bimekizumab in psoriatic disease: Introducing the BE UNIQUE phase 3b study
- DOI
- 10.1016/j.jid.2026.07.020
- Published
- 2026-09
- Container
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jid.2026.07.020,
title = {Investigating the molecular drivers of high-level clinical responses to bimekizumab in psoriatic disease: Introducing the BE UNIQUE phase 3b study},
author = {Johann E. Gudjonsson and Joseph F. Merola and Richard B. Warren and Iain B. McInnes and Balint Szilagyi and Christiane Simon-Hinsberg and Paul Jones and Joe Rastrick and Ann Cleverly and Ioana Cutcutache and James G. Krueger},
year = {2026},
journal = {Journal of Investigative Dermatology},
doi = {10.1016/j.jid.2026.07.020},
url = {https://doi.org/10.1016/j.jid.2026.07.020}
}RIS
TY - JOUR TI - Investigating the molecular drivers of high-level clinical responses to bimekizumab in psoriatic disease: Introducing the BE UNIQUE phase 3b study AU - Johann E. Gudjonsson AU - Joseph F. Merola AU - Richard B. Warren AU - Iain B. McInnes AU - Balint Szilagyi AU - Christiane Simon-Hinsberg AU - Paul Jones AU - Joe Rastrick AU - Ann Cleverly AU - Ioana Cutcutache AU - James G. Krueger PY - 2026 JO - Journal of Investigative Dermatology DO - 10.1016/j.jid.2026.07.020 UR - https://doi.org/10.1016/j.jid.2026.07.020 ER -
APA
Gudjonsson, J. E., Merola, J. F., Warren, R. B., McInnes, I. B., Szilagyi, B., Simon-Hinsberg, C., Jones, P., Rastrick, J., Cleverly, A., Cutcutache, I., & Krueger, J. G. (2026). Investigating the molecular drivers of high-level clinical responses to bimekizumab in psoriatic disease: Introducing the BE UNIQUE phase 3b study. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2026.07.020
Source records
- crossref · retrieved 2026-09-27T10:02:39.514Z